The Securities and Exchange Commission has not necessarily reviewed the information in this filing and has not determined if it is accurate and complete.
The reader should not assume that the information is accurate and complete.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 13F

FORM 13F INFORMATION TABLE
OMB APPROVAL
OMB Number: 3235-0006
Estimated average burden
hours per response: 23.8
COLUMN 1 COLUMN 2 COLUMN 3 COLUMN 4 COLUMN 5 COLUMN 6 COLUMN 7 COLUMN 8
VALUE SHRS OR SH/ PUT/ INVESTMENT OTHER VOTING AUTHORITY
NAME OF ISSUER TITLE OF CLASS CUSIP FIGI (to the nearest dollar) PRN AMT PRN CALL DISCRETION MANAGER SOLE SHARED NONE
Allakos, Inc. Common 01671P100   21,311,384 4,887,932 SH   OTR   3,349,223 1,538,709 0
Spruce Bioscience, Inc. Common 85209E109   6,313,005 2,936,281 SH   SOLE   2,936,281 0 0
Vapotherm, Inc. Common 922107107   188,014 417,808 SH   OTR   0 417,808 0
Mirum Pharmaceuticals, Inc. Common 604749101   41,938,323 1,621,118 SH   SOLE   1,621,118 0 0
Reneo Pharmaceuticals, Inc. Common 75974E103   16,624,483 2,534,220 SH   SOLE   2,534,220 0 0
Xilio Therapeutics, Inc. Common 98422T100   3,776,583 1,441,444 SH   SOLE   1,441,444 0 0